An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro.

This phase 1, randomized, one-day, five-period crossover study in adults with type 1 diabetes on continuous subcutaneous insulin infusion investigated local infusion site pain following infusion of the excipients of ultra rapid lispro (URLi; without insulin) across infusion sites and depths.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Forty participants (mean age, 40.5 years; body mass index [BMI], 27.5) were randomized to one of five infusion site sequences consisting of the arm, thigh, buttock (6 mm cannula depth), and abdomen (6 and 9 mm depth).

Participants rated their pain on a 0 to 100 mm validated visual analog scale (VAS) at 5 minutes pre-bolus and 1 and 15 minutes post-bolus.

How the Study Was Run

The design is described as randomized and crossover.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Insulin Lispro, Diabetes Mellitus, Type 1, Pain Measurement, Excipients, Hypoglycemic Agents, Infusions, Subcutaneous and Pain.

The authors tagged it with the keywords continuous subcutaneous insulin infusion, infusion site pain, insulin pump and visual analog scale.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Lispro.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Journal of diabetes science and technology), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.